Travere Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Travere Therapeutics
TVTX Stock  USD 19.84  1.03  4.94%   
Travere Therapeutics financial statements provide useful quarterly and yearly information to potential Travere Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Travere Therapeutics financial statements helps investors assess Travere Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Travere Therapeutics' valuation are summarized below:
Gross Profit
7.9 M
Profit Margin
(1.38)
Market Capitalization
1.9 B
Enterprise Value Revenue
8.075
Revenue
233.2 M
We have found one hundred twenty available fundamental trend indicators for Travere Therapeutics, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Travere Therapeutics current market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 1.4 B in 2025. Enterprise Value is likely to rise to about 1.8 B in 2025

Travere Therapeutics Total Revenue

177.24 Million

Check Travere Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Travere Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 16.1 M, Selling General Administrative of 277.3 M or Other Operating Expenses of 584.9 M, as well as many indicators such as Price To Sales Ratio of 6.84, Dividend Yield of 0.0 or PTB Ratio of 22.1. Travere financial statements analysis is a perfect complement when working with Travere Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Travere Therapeutics Correlation against competitors.
For more information on how to buy Travere Stock please use our How to Invest in Travere Therapeutics guide.

Travere Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets474.5 M594.1 M434 M
Slightly volatile
Short and Long Term Debt Total421.7 M401.6 M172.2 M
Slightly volatile
Other Current Liabilities64 M100.3 M58.6 M
Slightly volatile
Total Current Liabilities210.8 M200.8 M97 M
Slightly volatile
Accounts Payable13.9 M23.5 M12.7 M
Slightly volatile
Cash58.4 M58.5 M53.4 M
Slightly volatile
Cash And Short Term Investments292.8 M370.7 M267.8 M
Slightly volatile
Common Stock Total Equity3.5 K6.9 K3.5 K
Slightly volatile
Common Stock Shares Outstanding48.4 M78.9 M44.3 M
Slightly volatile
Liabilities And Stockholders Equity474.5 M594.1 M434 M
Slightly volatile
Non Current Liabilities Total215.1 M334.3 M196.8 M
Slightly volatile
Other Stockholder Equity1.6 B1.5 B627.8 M
Slightly volatile
Total Liabilities313.3 M535 M286.6 M
Slightly volatile
Total Current Assets325.8 M416.7 M298 M
Slightly volatile
Short Term Debt77.8 M74.1 M19.3 M
Slightly volatile
Common Stock9.4 K9 K4.2 K
Slightly volatile
Property Plant And Equipment Net11.2 M19.6 M9 M
Slightly volatile
Non Current Assets Total171.5 M177.4 M137.7 M
Slightly volatile
Other Current Assets8.4 M12.7 M6.7 M
Slightly volatile
Intangible Assets138.4 M104 M111.2 M
Slightly volatile
Short Term Investments292.9 M312.2 M218.1 M
Slightly volatile
Property Plant And Equipment Gross29.8 M28.4 M11.1 M
Slightly volatile
Net Receivables21.3 M27.1 M21.6 M
Pretty Stable
Good Will723 K800 K900.5 K
Slightly volatile
Inventory6.1 M6.2 M4.4 M
Slightly volatile
Other Liabilities67.7 M76.1 M88.2 M
Slightly volatile
Other Assets30.8 K32.4 K5.4 M
Slightly volatile
Long Term Debt268.1 M310.3 M158.4 M
Slightly volatile
Net Invested Capital507.4 M438.1 M410.3 M
Slightly volatile
Non Current Liabilities Other6.5 M6.8 M71.9 M
Slightly volatile
Net Working Capital376.8 M216 M299.9 M
Slightly volatile
Property Plant Equipment11.8 M10.4 M7.4 M
Slightly volatile
Short and Long Term Debt50.1 M79 M42.2 M
Slightly volatile
Capital Stock6.4 K9 K5 K
Slightly volatile
Long Term Debt Total172.3 M193.8 M211.3 M
Slightly volatile
Capital Surpluse1.1 B1.2 B891.2 M
Slightly volatile
Capital Lease Obligations23.4 M22.6 M28.5 M
Pretty Stable

Travere Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense16.1 M11.2 M14.7 M
Very volatile
Selling General Administrative277.3 M264.1 M120.9 M
Slightly volatile
Other Operating Expenses584.9 M557 M245.6 M
Slightly volatile
Total Operating Expenses584.9 M557 M243 M
Slightly volatile
Depreciation And Amortization45.7 M43.6 M18.9 M
Slightly volatile
Research Development132 M217.5 M105.8 M
Slightly volatile
Total Revenue177.2 M233.2 M128.9 M
Slightly volatile
Gross Profit171.9 M233.2 M125.1 M
Slightly volatile
Cost Of Revenue6.1 M7.7 M4.4 M
Slightly volatile
Reconciled Depreciation30.7 M43.6 M23.7 M
Slightly volatile
Interest Income10.8 M17.8 M7.7 M
Slightly volatile
Non Recurring77.7 M87.4 M95.3 M
Slightly volatile
Selling And Marketing Expenses30.1 M33.9 M37 M
Slightly volatile

Travere Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation45.7 M43.6 M19 M
Slightly volatile
End Period Cash Flow58.4 M58.5 M53.4 M
Slightly volatile
Stock Based Compensation27.9 M36.9 M24.6 M
Slightly volatile
Dividends Paid75 M84.3 M91.9 M
Slightly volatile
Net Borrowings117.5 M85.5 M176.9 M
Slightly volatile
Change To Netincome43.7 M37.4 M47.8 M
Very volatile
Issuance Of Capital Stock112.3 M134.7 M133.1 M
Very volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio6.845.89367.418
Slightly volatile
Days Sales Outstanding81.1542.44681.5404
Slightly volatile
Average Payables3.1 M4.8 M4.4 M
Slightly volatile
Stock Based Compensation To Revenue0.230.15830.302
Slightly volatile
Capex To Depreciation4.142.32384.5049
Slightly volatile
EV To Sales7.857.36488.6962
Slightly volatile
Inventory Turnover0.781.10.9052
Slightly volatile
Days Of Inventory On Hand438345425
Slightly volatile
Payables Turnover0.30.250.2932
Slightly volatile
Sales General And Administrative To Revenue0.81.13271.2678
Slightly volatile
Average Inventory827.4 K1.5 M1.2 M
Slightly volatile
Research And Ddevelopement To Revenue0.740.93281.1019
Slightly volatile
Capex To Revenue0.460.43410.1816
Slightly volatile
Cash Per Share4.294.6995.2937
Slightly volatile
Days Payables Outstanding1.6 K1.5 K2.2 K
Slightly volatile
Intangibles To Total Assets0.170.1750.4224
Slightly volatile
Current Ratio1.982.07572.5864
Slightly volatile
Receivables Turnover6.48.59926.7844
Slightly volatile
Capex Per Share1.351.2830.5806
Slightly volatile
Average Receivables31.8 M30.3 M24 M
Slightly volatile
Revenue Per Share2.622.95572.7031
Slightly volatile
Interest Debt Per Share5.495.23223.3327
Slightly volatile
Debt To Assets1.320.67590.849
Slightly volatile
Graham Number21.2123.8626.0093
Slightly volatile
Operating Cycle40.3242.446456
Slightly volatile
Days Of Payables Outstanding1.6 K1.5 K2.2 K
Slightly volatile
Long Term Debt To Capitalization1.180.84722.601
Slightly volatile
Quick Ratio1.942.04482.5511
Slightly volatile
Net Income Per E B T1.021.00320.9489
Slightly volatile
Cash Ratio0.380.29160.4972
Slightly volatile
Days Of Inventory Outstanding438345425
Slightly volatile
Days Of Sales Outstanding81.1542.44681.5404
Slightly volatile
Fixed Asset Turnover11.2811.877944.9793
Slightly volatile
Debt Ratio1.320.67590.849
Slightly volatile
Price Sales Ratio6.845.89367.418
Slightly volatile
Asset Turnover0.220.39250.2525
Slightly volatile
Gross Profit Margin1.071.060.9819
Slightly volatile

Travere Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.4 B1.4 B776.8 M
Slightly volatile
Enterprise Value1.8 B1.7 B899.7 M
Slightly volatile

Travere Fundamental Market Drivers

Cash And Short Term Investments370.7 M

Travere Upcoming Events

22nd of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Travere Therapeutics Financial Statements

Travere Therapeutics investors use historical fundamental indicators, such as Travere Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Travere Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue2.8 M2.7 M
Total Revenue233.2 M177.2 M
Cost Of Revenue7.7 M6.1 M
Stock Based Compensation To Revenue 0.16  0.23 
Sales General And Administrative To Revenue 1.13  0.80 
Research And Ddevelopement To Revenue 0.93  0.74 
Capex To Revenue 0.43  0.46 
Revenue Per Share 2.96  2.62 
Ebit Per Revenue(1.38)(1.44)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CRMSalesforce
CRMSalesforce

Additional Tools for Travere Stock Analysis

When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY